Preparation method and application of silver / copper alloy nanoparticles
The silver/copper alloy nanoparticles prepared by biosynthetic method solve the problems of poor stability and high toxicity of nanoparticles in traditional methods, achieving efficient killing in bacteria and cancer cells, and combining chemotherapy and thermal therapy, significantly improving antibacterial and Anti-cancer effect.
Patent Information
- Application Number
- CN202410982416.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art has problems such as poor stability, high toxicity, high cost, complex preparation process and difficult to control when preparing silver/copper alloy nanoparticles. In particular, single copper nanoparticles are easy to oxidize and single silver nanoparticles are expensive, and traditional methods It is harmful to the environment and human health.
Silver/copper alloy nanoparticles were prepared by biosynthesis method. By mixing copper salt and silver salt solution in ultrapure water, adding polyvinylpyrrolidone and ascorbic acid solution, heating and stirring in light, the reaction conditions were controlled to obtain stable and dispersible Cu@AgNPs nanoparticles.
Improves the biocompatibility and stability of nanoparticles, reduces the risk of release of silver and copper ions, exerts toxicity only in bacterial and cancer cell lesions, has multi-target killing effects, and can be used to combine chemotherapy and thermal therapy. treat.
Smart Images

Figure HDA0004956475790000011 
Figure HDA0004956475790000012 
Figure HDA0004956475790000021
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedical nanomaterials and relates to a preparation method of silver / copper alloy nanoparticles and application thereof. Background Art
[0002] With the intensification of environmental pollution, various sudden infections continue to threaten people's health and safety. About 54.3% of infections are caused by pathogenic microorganisms. Bacterial infection may cause inflammation, and chronic inflammation can lead to damage to cell DNA, thereby increasing the risk of malignant tumors. Cancer is a disease caused by the loss of normal regulation and excessive proliferation of body cells, which poses a major threat to human health. There are many types of cancer, which are prone to malignant behaviors such as spread and metastasis. Despite the continuous development of modern medicine, cancer is still difficult to treat and has become the leading cause of death in the world. In recent years, new inorganic metal chemotherapy drugs have gradually emerged, such as silver and copper nanoparticles, which have been widely explored and studied. However, single copper nanoparticles are easily oxidized and have weak stability, and single silver nanoparticles are expensive and have high toxicity. It is hoped that the alloys can be prepared to complement the advantages and disadvantages of the two metals. However, the current preparation strategy is not perfect.
[0003] At present, the common methods for preparing silver / copper alloy nanoparticles include chemical reduction method and physical synthesis method. Chemical reduction method is the most commonly used method for preparing nanoparticles in laboratories and industries. That is, a suitable soluble metal precursor is selected and reacted with an appropriate reducing agent (such as sodium borohydride, etc.) in a liquid phase system. The chemical reduction method is simple to operate and easy to control. The core formation process can be controlled by changing reaction parameters such as reaction temperature, time, and surfactant dosage, thereby controlling the particle size and morphology. However, oxidation or agglomeration is prone to occur during the reduction of copper nanoparticles by chemical reduction method, and chemical reagents need to be added, which has certain hazards to the environment and human health, limiting its practical application. The physical synthesis method mainly mixes silver and copper evenly by melt mixing or mechanical alloying, and then obtains the alloy by cooling and solidification. This method is simple and easy to operate, but it requires high temperature and high pressure conditions, and the alloy composition and morphology are difficult to control.
[0004] Due to the differences in redox potential and lattice constant, bimetallic nanoclusters containing silver and copper are not easy to be co-reduced. At the same time, the above methods are toxic, energy-intensive, complex, prone to oxidation or agglomeration, and the size of the alloy components cannot be controlled. Summary of the invention
[0005] In order to overcome the deficiencies of the prior art, the present invention provides a preparation method and application of silver / copper alloy nanoparticles. The alloy nanoparticles prepared by biosynthesis have high biocompatibility, stability and good dispersibility, and are effective in antibacterial and anticancer. The Cu@AgNPs nanoparticles provided by the present invention are expected to overcome the disadvantages of weak copper stability, physiological toxicity of silver itself and high price, which can not only improve biocompatibility, but also have better economic value. The silver-copper alloy nanoparticles prepared by this method are not easy to release silver ions and copper ions in advance under physiological conditions, causing physiological damage, and can remain stable during the blood circulation process including storage, and only exert toxicity at the bacterial and cancer cell lesions. At the same time, the introduction of copper ions can combine the new copper death mode and the common cell death mode to achieve the effect of multi-mechanism to eliminate cancer cells. In addition, the alloy nanoparticles have a good photothermal effect and can exist as a photosensitizer to realize a treatment mode combining chemotherapy and hyperthermia.
[0006] The above object of the present invention is achieved through the following technical solutions:
[0007] A method for preparing silver / copper alloy nanoparticles comprises the following steps:
[0008] S1. Mix the copper salt solution and the silver salt solution and place them in ultrapure water to obtain Cu 2+ and Ag + A mixed solution; adding polyvinyl pyrrolidone solution as a stabilizer; obtaining a preliminary mixed solution;
[0009] S2. The solution of step S1 is heated and stirred in dark and ascorbic acid solution is added dropwise; Solution A is obtained.
[0010] S3. Continue heating and stirring the solution A in step S2 to react and obtain the Cu@AgNPs solution B.
[0011] S4. Centrifuge the solution B in step S3, discard the supernatant, and precipitate Cu@AgNPs.
[0012] Furthermore, the copper salt solution in step S1 is a soluble copper salt solution, and the copper salt solution is any one or more of copper sulfate pentahydrate, copper nitrate trihydrate, and copper nitrate.
[0013] Furthermore, the silver salt solution in step S1 is a soluble silver salt solution, and the silver salt solution is any one of silver nitrate and silver acetate, or more than two of them.
[0014] Furthermore, in step S1, the copper salt solution and the silver salt solution are mixed and placed in 7-10 mL of ultrapure water. Furthermore, the copper salt solution and the silver salt solution in step S1 have the same concentration, which is 20-40 mM / L.
[0015] Furthermore, the volume ratio of the copper salt solution to the silver salt solution in step S1 is 1:1 to 1:4.
[0016] Furthermore, the concentration of the polyvinyl pyrrolidone solution in step S1 is 10-20 mg / mL, and the added amount is 1-5 mL.
[0017] Furthermore, the heating temperature in step S2 is 60-75°C.
[0018] Furthermore, the concentration of the ascorbic acid solution in step S2 is 100-200 mM / L, and the amount added is 0.5-2 mL.
[0019] Furthermore, the pH value of the ascorbic acid solution in step S2 is 3-5.
[0020] Furthermore, the centrifugal speed in step S4 is 10000-15000 rpm.
[0021] Furthermore, the centrifugation time in step S4 is 10 to 20 minutes.
[0022] Furthermore, the particle size of the silver / copper alloy nanoparticles Cu@AgNPs prepared by the above preparation method is 80-100 nm.
[0023] The present invention also seeks to protect the use of the silver / copper alloy nanoparticles Cu@AgNPs prepared by the above preparation method in the preparation of inhibitory drugs for foodborne pathogens.
[0024] The present invention also seeks to protect the use of the silver / copper alloy nanoparticles Cu@AgNPs prepared by the above preparation method in the preparation of inhibitory drugs for breast cancer cells.
[0025] However, the method provided by the present invention can successfully prepare silver / copper alloy nanoparticles Cu@AgNPs with alloy structure. And through the analysis of physical and chemical properties such as morphology and particle size, it is concluded that the alloy nanoparticles have uniform particle size and good dispersion stability.
[0026] The beneficial effects of the present invention compared with the prior art are:
[0027] The present invention overcomes the traditional chemical reduction method and physical synthesis method, fills the gap of domestic and foreign professional technology, and uses the biological reduction method to construct the fused silver / copper alloy nanoparticles Cu@AgNPs to overcome the disadvantage of easy oxidation of copper, while weakening the toxicity of silver and the disadvantage of high price, not only increasing the biocompatibility, but also increasing the stability of the alloy nanoparticles, and having better economic value. The preparation method is simple, the obtained nanoparticles have uniform particle size, good purity, and good adjustability, and the ratio of silver and copper elements in the nanoalloy can be effectively adjusted by adjusting the input amount of the reaction precursor, and the synthesized nanoalloy has rich component adjustability. The optimal ratio of silver and copper components in the silver / copper alloy nanoparticles can be selected to determine the balance point of its high anticancer activity and low physiological toxicity, and synthesize Cu@AgNPs to achieve the effect of complementary advantages and learning from each other's strengths and weaknesses. Ascorbic acid is used as a reducing agent, and the preparation process is safe and non-toxic. The prepared silver / copper alloy nanoparticles remain stable during the blood circulation process, including the storage process, that is, it is not easy to release silver ions and copper ions prematurely under physiological conditions to cause physiological damage, and only exert toxicity at the bacterial and cancer cell lesions. This is particularly important for medical applications and helps to reduce the side effects of drugs. The prepared nanoparticles can combine the new death mode copper death with the traditional cell death mode, have a multi-target killing effect, and have a good photothermal effect. They can be used as photosensitizers and can also achieve drug co-delivery combined with chemotherapy and hyperthermia. This safe and efficient preparation method can be applied in many fields such as antibacterial and anti-cancer. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments.
[0029] Figure 1 The physicochemical property analysis diagrams of the silver / copper alloy nanoparticles Cu@AgNPs prepared in Example 1 of the present invention, wherein Figure (a) is a scanning electron microscope SEM diagram, Figure (b) is an elemental analysis EDX diagram, and Figure (c) is a transmission electron microscope TEM diagram.
[0030] Figure 2 The results of the inhibition of E. coli by silver / copper alloy nanoparticles prepared in Example 1 of the present invention are shown in Figure (a) for the AgNPs control group and Figure (b) for the Cu@AgNPs drug group.
[0031] Figure 3 This is a graph showing the cytotoxicity test results of silver / copper alloy nanoparticles prepared by the present invention on MDA-MB-231 cells. DETAILED DESCRIPTION
[0032] The present invention is described in detail below by specific examples, but the protection scope of the present invention is not limited. Unless otherwise specified, the experimental methods used in the present invention are all conventional methods, and the experimental equipment, materials, reagents, etc. used can be obtained from commercial channels.
[0033] The invention belongs to the field of biomedical nanomaterials. The preparation method comprises the steps of preparing Cu containing polyvinyl pyrrolidone. 2+ and Ag + Mix the solution, add ascorbic acid solution, adjust the parameters to prepare Cu@AgNPs nanoparticles, the nanoparticles thus prepared have a particle size of 80 to 100 nm, and are used in the preparation of inhibitory drugs for foodborne pathogens and conventional breast cancer cells. The silver / copper alloy nanoparticles (Cu@AgNPs) prepared by the present invention are simple, fast, and easy to operate. The silver / copper alloy nanoparticles provided by the present invention integrate the activities of silver and copper metal nanoparticles, that is, overcome the disadvantage of copper being easily oxidized, while weakening the toxicity of silver and the disadvantage of being expensive, not only increasing biocompatibility, but also having better economic value, having higher stability and better dispersibility, and having good photothermal effect, and can be used as a photosensitive material to combine chemotherapy with hyperthermia to make it effective in antibacterial and anticancer.
[0034] Example 1
[0035] The preparation method of silver / copper alloy nanoparticles for antibacterial and anticancer use comprises the following specific steps:
[0036] (1) Use a microsampler to transfer 40 mmol copper nitrate solution and 40 mmol silver nitrate solution respectively; make the volume ratio of the two solutions in the reaction solution be 1:1, stir evenly in 7 mL ultrapure water, and then add 2 mL of 20 mg / L polyvinyl pyrrolidone solution as a stabilizer.
[0037] (2) Heat and stir at 75°C in the dark for 10 min, and add 500 μL of 200 mM / L ascorbic acid solution to obtain silver / copper alloy nanoparticle solution A. Heat and stir the silver / copper alloy nanoparticle solution A at 75°C for 10 min to obtain silver / copper alloy nanoparticle solution B. The color of the obtained silver / copper alloy nanoparticle solution B is brick red.
[0038] (3) Centrifugal separation to obtain a silver / copper alloy nanoparticle solution B with higher purity. The centrifugal conditions are 12000rpm, 20min, centrifugation once, and the supernatant is discarded. The precipitate is Cu@AgNPs. The precipitate is resuspended in 1mL of ultrapure water and stored in the dark. The physicochemical properties of the nanoparticles Cu@AgNPs provided by the present invention are then analyzed. Figure 1 The present invention provides a scanning electron microscope (SEM), elemental analysis (EDX) and transmission electron microscope (TEM) image of the silver / copper alloy nanoparticles. The SEM and TEM results are consistent with the dynamic light scattering (DLS) analysis results, and the particle size is 97.28±0.40nm, and the size is uniform.
[0039] Stability experiment: The average particle size, PDI value and Zeta potential of the prepared Cu@AgNPs samples were measured by DLS method. The specific method is as follows: 3mL of ultrapure water was added to the cuvette, and after being evenly mixed with 100μL of Cu@AgNPs, the cuvette was placed in an ultrasonic cleaner for 2min to remove bubbles in the cuvette, and the surface of the cuvette was wiped dry with absorbent paper, and placed in the measuring tank, and the DLS mode was selected. After the measurement of Cu@AgNPs was named, the measurement was started, and the measurement was performed three times in total. The average value of the three measurements was the result. After the particle size measurement was completed, part of the sample was sucked away, and the electrode sheet was inserted into the cuvette so that the liquid surface covered the electrode sheet. The cuvette was placed in the measuring tank again, and the ELS mode was selected. After the measurement of the sample, the measurement was performed after the name of the measurement sample. The average value after the three measurements was the Zeta potential value required for the experiment.
[0040] Table 1 shows the particle size, PDI value, and Zeta potential of the Cu@AgNPs suspension measured within 7 days, and no obvious changes were observed within 7 days, proving that the obtained Cu@AgNPs have good stability.
[0041] Table 1 Particle size, Zeta potential, and PDI value of Cu@AgNPs (7 days)
[0042] sample Size(nm) PDI ZetaPotential(mV) Cu@AgNPsday(1) 97.28±0.40 0.309±0.005 -16.85±1.68 Cu@AgNPsday(3) 97.63±0.58 0.310±0.004 -19.29±2.06 Cu@AgNPsday(5) 98.52±1.97 0.306±0.016 -19.22±0.97 Cu@AgNPsday(7) 97.31±0.27 0.309±0.007 -17.58±2.48
[0043] Inhibition zone experiment: After the prepared LB and solid culture medium are sterilized by high-pressure steam, they are left to stand until the temperature drops to about 55-60°C, and then about 2% (v / v) Escherichia coli solution is added. After the components are fully mixed, they are poured into the culture dish so that the volume of the solid culture medium in the culture dish is 25mL. Before the culture medium solidifies, 4 Oxford cups are placed in the culture dish. After the culture medium solidifies, in order to prevent the culture medium from being destroyed, the Oxford cup is taken out vertically with tweezers. After the Oxford cup is taken out, a hollow groove will be formed at its corresponding position. Then, 200μL / well of Cu@AgNPs suspension (concentration 300μg / mL) is added to the groove, which is the Cu@AgNPs drug group; and AgNPs is set as the control group, and 200μL / well of AgNPs suspension (concentration 300μg / mL) is added to the groove. The culture dishes were then placed in a 37°C constant temperature incubator and cultured for 12 hours. After the culture time was over, the inhibitory effects of Cu@AgNPs and AgNPs on Escherichia coli were preliminarily compared based on the diameters of the inhibition zones. The larger the average diameter of the inhibition zone, the better the antibacterial effect.
[0044] Depend on Figure 2 It can be seen that the Cu@AgNPs drug group has better effect than the single-component AgNPs control group. The inhibitory effect on Escherichia coli is compared based on the size of the inhibition zone diameter. The larger the average diameter of the inhibition zone, the better the antibacterial effect.
[0045] In vitro anticancer activity analysis (MTT method): Human breast cancer MDA-MB-231 cells in the logarithmic growth phase were routinely washed, digested with trypsin, and centrifuged to prepare a cell suspension at an appropriate cell density (5×10 3 The cells were inoculated into 96-well plates and incubated in a cell culture incubator at 37°C and 5% CO2 for 24 h. After the cells adhered to the wall, the culture medium was discarded and the MDA-MB-231 cells were treated with different concentrations of Cu@AgNPs and continued to be incubated in a cell culture incubator at 37°C and 5% CO2 for 24 h. The Cu@AgNPs group was the drug treatment group and the Cu@AgNPs+NIR group was the drug treatment plus laser group (the drug treatment plus laser group had an increase of 5 W / cm2 1 h after drug treatment). 2 After the drug effect ended, 20 μL of 5 mg / mL MTT was added to each cell culture well. After incubation for 4 h, 100 μL of DMSO was added to each well in a microplate reader. The cells were incubated at 37 °C with intermittent shaking for 10 min to completely dissolve the MTT reduction product. The OD values at 570 nm and 650 nm were detected to calculate the cell survival rate.
[0046] Figure 2 The cytotoxicity of different drug formulations on MDA-MB-231 cells was Figure 3 The results show that Cu@AgNPs can combine the activities of the two metal particles. Under the joint action of the two metal particles, Cu@AgNPs may have stronger anticancer activity, which is manifested in that the survival rate of cancer cells is 24.11% at a concentration of 45μg / mL, and has a lower IC 50 In addition, it was calculated that the cytotoxicity of silver / copper alloy nanoparticles combined with near-infrared laser irradiation was the strongest, IC 50 The concentration of the silver / copper alloy nanoparticles in the present invention was 25-30 μg / mL, which was significantly lower than that in the group without laser. This preliminarily proves that the combined use of the silver / copper alloy nanoparticles and photothermal therapy provided by the present invention significantly improves the anticancer activity of the alloy nanoparticles, laying a foundation for further research on the alloy nanoparticles.
[0047] The above-described embodiments are only preferred embodiments of the present invention, but not all feasible embodiments of the present invention. For those skilled in the art, any obvious changes made thereto without departing from the principles and spirit of the present invention should be considered to be included in the scope of protection of the claims of the present invention.
Claims
1. A method for preparing silver / copper alloy nanoparticles, characterized in that: The following steps are involved: S1. Mix the copper salt solution and the silver salt solution and place them in ultrapure water to obtain Cu 2+ and Ag + A mixed solution of polyvinyl pyrrolidone solution was added as a stabilizer; Obtaining a preliminary mixed solution; S2. The preliminary mixed solution of step S1 is heated in dark and stirred and ascorbic acid solution is added dropwise; Get solution A S3. Continue heating and stirring the solution A in step S2 to react and obtain the Cu@AgNPs solution B. S4. Centrifuge the solution B in step S3, discard the supernatant, and precipitate Cu@AgNPs.
2. The method for preparing silver / copper alloy nanoparticles according to claim 1, wherein: The concentrations of the copper salt solution and the silver salt solution in step S1 are the same.
3. The method for preparing silver / copper alloy nanoparticles according to claim 1, characterized in that: The volume ratio of the copper salt solution to the silver salt solution in step S1 is 1:1 to 1:
4.
4. The method for preparing silver / copper alloy nanoparticles according to claim 1, wherein: The concentration of the polyvinyl pyrrolidone solution in step S1 is 10-20 mg / mL, and the added amount is 1-5 mL.
5. The method for preparing silver / copper alloy nanoparticles according to claim 1, wherein: The heating temperature in step S2 is 60-75°C.
6. The method for preparing silver / copper alloy nanoparticles according to claim 1, characterized in that: The concentration of the ascorbic acid solution in step S2 is 100-200 mM / L, and the amount added is 0.5-2 mL.
7. The method for preparing silver / copper alloy nanoparticles according to claim 1, characterized in that: The pH value of the ascorbic acid solution in step S2 is 3-5.
8. The method for preparing silver / copper alloy nanoparticles according to claim 1, wherein: The particle size of the silver / copper alloy nanoparticles Cu@AgNPs prepared by the preparation method is 80-100 nm.
9. Use of the silver / copper alloy nanoparticles Cu@AgNPs prepared by the preparation method according to any one of claims 1 to 8 in the preparation of drugs for inhibiting foodborne pathogens.
10. Use of the silver / copper alloy nanoparticles Cu@AgNPs prepared by the preparation method according to any one of claims 1 to 8 in preparing drugs for inhibiting breast cancer cells.
